Concerning study 2, including patients with BD in partial remission, it cannot be excluded that the effect of EPO versus placebo on BDNF levels would be different among patients in a severe depressive state in line with a recent review pointing at peripheral BDNF levels as a biomarker of disease activity [52]. The gene discussed is BDNF; the disease is Behcet disease.